drugset / Trial / NCT05853367
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
Timeline
- Start
- 2023-07-06
- Primary completion
- 2028-06-24
- Completion
- 2028-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calderasib | Unknown | — | Oral |
| Subject | MK-0472 | Unknown | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |